Genix Pharmaceuticals Corporation
GENPF · OTC
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $3 | $3 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | – | $4 | $4 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | – | – | – | -1,476.5% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 279,050% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 226,436.8% |
| EPS Diluted | -0.001 | -0.001 | -0.002 | 0.003 |
| % Growth | -11.1% | 50% | -169.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |